Neonatal candidiasis: Prophylaxis and treatment

Expert Opinion on Pharmacotherapy

Volumn 6, Issue 10, 2005, Pages 1647-1655

  Tiffany, Kenneth F ^a   Smith, Phillip B ^a,b   Benjamin Jr , Daniel K ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Antifungal therapy; Candida; Neonatal intensive care unit

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CARBAPENEM; CASPOFUNGIN; CEPHALOSPORIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; MICONAZOLE; NYSTATIN; PLACEBO; VORICONAZOLE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANEMIA; BONE MARROW SUPPRESSION; CANDIDIASIS; CHILL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL DISEASE; HUMAN; HYPOKALEMIA; INCIDENCE; KIDNEY FAILURE; MENINGITIS; MORTALITY; NEPHROTOXICITY; NEWBORN; NEWBORN INFECTION; NEWBORN INTENSIVE CARE; NONHUMAN; PHOTOSENSITIVITY; PREMATURITY; RETINOPATHY; REVIEW; RIGOR; RISK FACTOR; SURVIVAL; TORSADE DES POINTES; VISUAL DISORDER;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDIASIS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FLUCONAZOLE; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 23844495595     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.6.10.1647     Document Type: Review

References (85)

1. BENJAMIN DK Jr, DELONG ER, STEINBACH WJ, COTTON CM, WALSH TJ, CLARK RH: Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics (2003) 112(3 Pt 1):543-547.
2. SAIMAN L, LUDINGTON E, DAWSON JD et al.: Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr. Infect. Dis. J. (2001) 20(12):1119-1124.
3. KAUFMAN D: Strategies for prevention of neonatal invasive candidiasis. Semin. Perinatol. (2003) 27(5):414-424.
4. BOTAS CM, KURLAT I, YOUNG SM, SOLA A: Disseminated candidal infections and intravenous hydrocortisone in preterm infants. Pediatrics (1995) 95(6):883-887.
5. CHAPMAN RL, FAIX RG: Persistently positive cultures and outcome in invasive neonatal candidiasis. Pediatr. Infect. Dis. J. (2000) 19(9):822-827.
6. BENJAMIN DK Jr, POOLE C, STEINBACH WJ, ROWEN JL, WALSH TJ: Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics (2003) 112(3 Pt 1):634-640.
7. DARMSTADT GL, DINULOS JG, MILLER Z: Congenital cutaneous candidiasis: clinical presentation, pathogenesis, and management guidelines. Pediatrics (2000) 105(2):438-444.
8. FAIX RG, CHAPMAN RL: Central nervous system candidiasis in the high-risk neonate. Semin Perinatol. (2003) 27(5):384-392.
9. LEE BE, CHEUNG PY, ROBINSON JL, EVANOCHKO C, ROBERTSON CM: Comparative study of mortality and morbidity in premature infants (birth weight, < 1,250 g) with candidemia or candidal meningitis. Clin. Infect. Dis. (1998) 27(3):559-565.
10. KARLOWICZ MG: Candidal renal and urinary tract infection in neonates. Semin. Perinatol. (2003) 27(5):393-400.
11. BRYANT K, MAXFIELD C, RABALAIS G: Renal candidiasis in neonates with candiduria. Pediatr. Infect. Dis. J. (1999) 18(11):959-963.
12. BENJAMIN DK, DELONG E, COTTEN CM, GARGES HP, STEINBACH WJ, CLARK RH: Mortality following blood culture in premature infants: increased with Gram-negative bacteremia and candidemia, but not Gram-positive bacteremia. J. Perinatol. (2004) 24(3):175-180.
13. STOLL BJ, HANSEN N, FANAROFF AA et al.: Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics (2002) 110(2 Pt 1):285-291.
14. STOLL BJ, GORDON T, KORONES SB et al.: late-onset sepsis in very low birth weight neonates: a report from the National Institute of Child Health and Human Development Neonatal Research Network. J. Pediatr. (1996) 129(1):63-71.
15. KOSSOFF EH, BUESCHER ES, KARLOWICZ MG: Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr. Infect. Dis. J. (1998) 17(6):504-508.
16. BENJAMIN DK Jr, FISHER RG, MCKINNEY RE Jr, BENJAMIN DK: Candidal mycetoma in the neonatal kidney. Pediatrics (1999) 104(5 Pt 1):1126-1129.
17. FRIEDMAN S, RICHARDSON SE, JACOBS SE, O'BRIEN K: Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr. Infect. Dis. J. (2000) 19(6):499-504.
18. SAIMAN L, LUDINGTON E, PFALLER M et al.: Risk factors for candidemia in Neonatal Intensive Care Unit patients. The National Epidemiology of Mycosis Survey study group. Pediatr. Infect. Dis. J. (2000) 19(4):319-324.
19. BENJAMIN DK Jr, STOLL BJ, FANAROFF AA et al.: Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality, and neurodevelopmental outcomes at 18-22 months. Pediatrics (2005) (In press).
20. BALEY JE, KLIEGMAN RM, BOXERBAUM B, FANAROFF AA: Fungal colonization in the very low birth weight infant. Pediatrics (1986) 78(2):225-232.
21. ROWEN JL, RENCH MA, KOZINETZ CA, ADAMS JM Jr, BAKER CJ: Endotracheal colonization with Candida enhances risk of systemic candidiasis in very low birth weight neonates. J. Pediatr. (1994) 124(5 Pt 1):789-794.
22. HUANG YC, LI CC, LIN TY et al.: Association of fungal colonization and invasive disease in very low birth weight infants. Pediatr. Infect. Dis J. (1998) 17(9):819-822.
23. PIZZO PA, ROBICHAUD KJ, GILL FA, WITEBSKY FG: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am. J. Med. (1982) 72(1):101-111.
24. SCHELONKA RL, MOSER SA: Time to positive culture results in neonatal Candida septicemia. J Pediatr. (2003) 142(5):564-565.
25. BENJAMIN DK Jr, STOLL BJ, FANAROFF AA et al.: Neonatal candidiasis among infants < 1000g birthweight: risk Factors, mortality, and neuro-developmental outcomes at 18-22 months. Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (2004).
26. KARLOWICZ MG, HASHIMOTO LN, KELLY RE Jr, BUESCHER ES: Should central venous catheters be removed as soon as candidemia is detected in neonates? Pediatrics (2000) 106(5): E63.
27. EPPES SC, TROUTMAN JL, GUTMAN LT: Outcome of treatment of candidemia in children whose central catheters were removed or retained. Pediatr. Infect. Dis. J. (1989) 8(2):99-104.
28. ROWEN JL, TATE JM: Management of neonatal candidiasis. Neonatal Candidiasis Study Group. Pediatr. Infect. Dis. J. (1998) 17(11):1007-1011.
29. MINARI A, HACHEM R, RAAD I: Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. Clin. Infect. Dis. (2001) 32(2):186-190.
30. ROILIDES E, FARMAKI E, EVDORIDOU J et al.: Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur. J. Clin. Microbiol. Infect. Dis. (2004) 23(10):745-750.
31. BALEY JE, MEYERS C, KLIEGMAN RM, JACOBS MR, BLUMER JL: Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J. Pediatr. (1990) 116(5):791-797.
32. SERRA G, MEZZANO P, BONACCI W: Therapeutic treatment of systemic candidiasis in newborns. J. Chemother. (1991) 3(Suppl. 1):240-244.
33. JUSTER-REICHER A, FLIDEL-RIMON O, AMITAY M, EVEN-TOV S, SHINWELL E, LEIBOVITZ E: High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. Eur. J. Clin. Microbiol. Infect. Dis. (2003) 22(10):603-607.
34. BALEY JE, KLIEGMAN RM, FANAROFF AA: Disseminated fungal infections in very low-birth-weight infants: therapeutic toxicity. Pediatrics (1984) 73(2):153-157.
35. KINGO AR, SMYTH JA, WAISMAN D: Lack of evidence of amphotericin B toxicity in very low birth weight infants treated for systemic candidiasis. Pediatr. Infect. Dis. J. (1997) 16(10):1002-1003.
36. LINDER N, KLINGER G, SHALIT I et al.: Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J. Antimicrob. Chemother. (2003) 52(4):663-667.
37. BEKERSKY I, FIELDING RM, DRESSLER DE, LEE JW, BUELL DN, WALSH TJ: Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. (2002) 46(3):828-833.
38. SCARCELLA A, PASQUARIELLO MB, GIUGLIANO B, VENDEMMIA M, DE LUCIA A: Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr. Infect. Dis. J. (1998) 17(2):146-148.
39. WEITKAMP JH, POETS CF, SIEVERS R et al.: Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection (1998) 26(1):11-15.
40. GROLL AH, WURTHWEIN G, HEMPEL G, ADLER-SHOHET F, LIEBERMAN JM, WALSH TJ: Pharmacokinetics of amphotericin B lipid complex in neonates. 43 Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2003).
41. JARLOV JO, BORN P, BRUUN B: Candida albicans meningitis in a 27 weeks premature infant treated with liposomal amphorericin-B (AmBisome). Scand. J. Infect. Dis. (1995) 27(4):419-420.
42. FERRARI P, CHIAROLANZA J, CAPRIOTTI T, GARETTI E, VENUTA A: [Favorable course of cerebral candidiasis in a low-birth newborn treated with liposomal amphotericin B]. Pediatr Med. Chir. (2001) 23(3-4):197-199.
43. BENNETT J: The Pharmacological Basis of Therapeutics (9th Edition). JG Hardman, LE Limbard, McGraw-Hill, New York, NY, USA (1996):1179.
44. FRATTARELLI DA, REED MD, GIACOIA GP, ARANDA JV: Antifungals in systemic neonatal candidiasis. Drugs (2004) 64(9):949-968.
45. SMEGO RA Jr, PERFECT JR, DURACK DT: Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis. Rev. Infect. Dis. (1984) 6(6):791-801.
46. WENZL TG, SCHEFELS J, HORNCHEN H, SKOPNIK H: Pharmacokinetics of oral fluconazole in premature infants. Eur. J. Pediatr. (1998) 157(8):661-662.
47. SAXEN H, HOPPU K, POHJAVUORI M: Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin. Pharmacol. Ther. (1993) 54(3):269-277.
48. FASANO C, O'KEFFE J, GIBBS D: Fluconazole treatment of neonates and infants with severe fungal infections not treatable with conventional agents. Eur. J. Clin. Microbiol. Infect. Dis. (1994) 13(4):351-354.
49. DRIESSEN M, ELLIS JB, COOPER PA et al.: Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr. Infect. Dis. J. (1996) 15(12):1107-1112.
50. HUTTOVA M, HARTMANOVA I, KRALINSKY K et al.: Candida fungemia in neonates treated with fluconazole: report of forty cases, including eight with meningitis. Pediatr. Infect. Dis. J. (1998) 17(11):1012-1015.
51. PFALLER MA, MESSER SA, HOLLIS RJ et al.: Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn. Microbiol. Infect. Dis. (1999) 33(4):217-222.
52. ROWEN JL, TATE JM, NORDOFF N, PASSARELL L, MCGINNIS MR: Candida isolates from neonates: frequency of misidentification and reduced fluconazole susceptibility. J. Clin. Microbiol. (1999) 37(11):3735-3737.
53. MARICHAL P, KOYMANS L, WILLEMSENS S et al.: Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology (1999) 145(Pt 10):2701-2713.
54. SANGLARD D: Clinical relevance of mechanisms of antifungal drug resistance in yeasts. Enferm. Infec. Microbiol. Clin. (2002) 20(9):462-469.
55. MULLER FM, WEIG M, PETER J, WALSH TJ: Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J. Antimicrob. Chemother. (2000) 46(2):338-340.
56. MAPLES HD, STOWE CD, SACCENTE SL, JACOBS RF: Voriconazole serum concentrations in an infant treated for Trichosporon beigelii infection. Pediatr. Infect. Dis. J. (2003) 22(11):1022-1024.
57. WALSH TJ, ARGUEDAS A, DRISCOLL T et al.: Pharmacokinetics of intravenous voriconazole in children after single and multiple dose administration. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA (2001).
58. WALSH TJ, LUTSAR I, DRISCOLL T et al.: Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Infect. Dis. J. (2002) 21(3):240-248.
59. BARTIZAL K, GILL CJ, ABRUZZO GK et al.: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41(11):2326-2332.
60. WALSH TJ, VIVIANI MA, ARATHOON E et al.: New targets and delivery systems for antifungal therapy. Med. Mycol. (2000) 38(Suppl. 1):335-347.
61. ODIO CM, ARAYA R, PINTO LE et al.: Caspofungin therapy of neonates with invasive candidiasis. Pediatr. Infect. Dis. J. (2004) 23(12):1093-1097.
62. WALSH TJ, ADAMSON PC, SEIBEL NL, AL E: Pharmacokinetics of caspofungin in pediatric patients (abstract). Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (2002).
63. MORA-DUARTE J, BETTS R, ROTSTEIN C et al.: Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. (2002) 347(25):2020-2029.
64. FRANKLIN JA, MCCORMICK J, FLYNN PM: Retrospective study of the safety of caspofungin in immunocompromised pediatric patients. Pediatr. Infect. Dis. J. (2003) 22(8):747-749.
65. HAJDU R, THOMPSON R, SUNDELOF JG et al.: Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41(11):2339-2344.
66. HOSSAIN MA, REYES GH, LONG LA, MUKHERJEE PK, GHANNOUM MA: Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans. J. Antimicrob. Chemother. (2003) 51(6):1427-1429.
67. HERESI G, GERSTMANN D, BLUMER J et al.: A Pharmacokinetic study of micafungin (FK463) in premature infants (Abstract). Pediatric Academic Society. Seattle, WA, USA (2003).
68. BENJAMIN DK, DRISCOLL T, SIEBEL N et al.: Safety and pharmacokinetics of anidulafungin in pediatric patients with neutropenia. Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, USA (2004).
69. SIMS ME, YOO Y, YOU H, SALMINEN. C, WALTHER FJ: Prophylactic oral nystatin and fungal infections in very-low-birthweight infants. Am. J. Perinatol. (1988) 5(1):33-36.
70. WAINER S, COOPER PA, FUNK E, BENTAL RY, SANDLER DA, PATEL J: Prophylactic miconazole oral gel for the prevention of neonatal fungal rectal colonization and systemic infection. Pediatr. Infect. Dis. J. (1992) 11(9):713-716.
71. VIOLARIS K, DORAISWAMY B, OLAWEPO O, GULRAJANI-LACORTE M: Fluconazole vs. nystatin prophylaxis for fungal infection in very low birth weight (VLBW) infants. Pediatric Research (1998) 43:254A.
72. AUSTIN NC, DARLOW B: Prophylactic oral antifungal agents to prevent systemic candida infection in preterm infants. Cochrane Database Syst. Rev. (2004) (1):CD003478.
73. BRAMMER KW, COATES PE: Pharmacokinetics of fluconazole in pediatric patients. Eur. J. Clin. Microbiol. Infect. Dis. (1994) 13(4):325-329.
74. GOODMAN JL, WINSTON DJ, GREENFIELD RA et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N. Engl. J. Med. (1992) 326(13):845-851.
75. LUMBRERAS C, CUERVAS-MONS V, JARA P et al.: Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis. (1996) 174(3):583-588.
76. SLAVIN MA, OSBORNE B, ADAMS R et al.: Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J. Infect. Dis. (1995) 171(6):1545-1552.
77. LEWIS RE, KLEPSER ME: The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy. Am. J. Health. Syst. Pharm. (1999) 56(6):525-533.
78. WHITE TC, PFALLER MA, RINALDI MG, SMITH J, REDDING SW: Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis. (1997) 3(Suppl. 1): S102-S109.
79. WHITE TC: The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans. Antimicrob. Agents Chemother. (1997) 41(7):1488-1494.
80. WHITE TC: Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. (1997) 41(7):1482-1487.
81. FAIRCHILD KD, TOMKORIA S, SHARP EC, MENA FV: Neonatal Candida glabrata sepsis: clinical and laboratory features compared with other Candida species. Pediatr. Infect. Dis. J. (2002) 21(1):39-43.
82. KICKLIGHTER SD, SPRINGER SC, COX T, HULSEY TC, TURNER RB: Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics (2001) 107(2):293-298.
83. KAUFMAN D, BOYLE R, HAZEN KC, PATRIE JT, ROBINSON M, DONOWITZ LG: Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N. Engl. J. Med. (2001) 345(23):1660-1666.
84. LEMONS JA, BAUER CR, OH W et al.: Very low birth weight outcomes of the National Institute of Child health and human development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. Pediatrics (2001) 107(1): E1.
85. JOHNSSON H, EWALD U: The rate of candidaemia in preterm infants born at a gestational age of 23-28 weeks is inversely correlated to gestational age. Acta Paediatr. (2004) 93(7):954-958.